Enhancing Digital Platform Capability and Networking Capability with Dynamic Enterprise Architecture Capabilities:In the view of market and technological turbulence

Autor: Dijkman, J. (Jordy)

This study conceptualizes and defines enterprise architecture-based (EA) capabilities, following the dynamic capabilities view, which tries to explain how dynamic enterprise architecture capabilities (DEAC) enhance digital platform capabilities (DPC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4301::766241a2f158bda52c70e5373f406655
https://research.ou.nl/en/studentTheses/453a7767-a14f-47ed-87f4-8a2f1274f358

Prophylactic treatment of grass pollen-induced asthma with cetirizine.

Autor: Dijkman, J. H.¹, Hekking, P. R. M.², Molkenboer, J. F.³, Nierop, G., anderschueren, R.⁴, Bernheim, J.⁵, van Ganse, E. H.⁵

Publikováno v: Clinical & Experimental Allergy. Sep1990, Vol. 20 Issue 5, p483-490. 8p.

Research Into Use : investigating the relationship between agricultural research and innovation

Autor: Hall, A., Dijkman, J., Sulaiman V., R.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::fe0ff0c756d7b015aeff957388cb4548
https://cris.maastrichtuniversity.nl/en/publications/07614495-8e22-4cbf-8f8e-d8364353a3c1

Private capacity and public failure: contours of livestock innovation response capacity in Kenya

Autor: Keskin, E., Steglich, M., Dijkman, J., Hall, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::bbc1dad2a791d3c86136b295d5ea1321
https://cris.maastrichtuniversity.nl/en/publications/d8faf028-98d7-4492-9584-5c04f3a82781

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

Autor: Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L.F., Weverling, G. J., Reiss, P., Duurvoort, M., Krijger, E., Brouwer, E., Visser, G. R., Klotz, A., Benschop, C., Wulfert, F., Wolf, F. De, Jurriaans, S., Portegies, P., Colebunders, R., Pelgrom, J., Wijnants, H., DE Roo, A., Keersmaekers, K., Vandenbruane, M., Branden, D. Van Den, James, T., Wanzeele, F. Van, Gucht, B. Van Der, Van Der Ende, M. E., Nouwen, J., Deenenkamp, R., Van Der Meyden, D., Koopmans, P. P., Brinkman, K., Ver Hofstede, H., Zomer, B., Blok, W. L., Ruissen, C., Sprenger, H., Law, G., Meulen, P. Vander, Veen, C. Ten, Juttmann, J. R., Heul, C. Vander, Santegoets, R., Ven, B. Vander, Kate, R. W.Ten, Schoemaker, M., Kauffmann, R. H., Henrichs, J. M., Maat, A., Prins, E., Napel, C. H.H.Ten, Pogany, K., Duyts, T., Simons, P., Lacor, P., Waele, A. De, Wijngaarden, E. Van, Lejeune, M., Nieuwkerk, P., Sprangers, M., Roos, M., Scholte, R., Dijkman, J., Japour, A. J., Borst, M. J., Leeuwen, E. Van

Publikováno v: Clinical Infectious Diseases, 31(5), 1234-1239. Oxford University Press
Clinical Infectious Diseases, 31(5), 1234-1239
Gisolf, E H, Dreezen, C, Danner, S A, Weel, J L F, Weverling, G J, Reiss, P, Weverling, G J, Duurvoort, M, Krijger, E, Brouwer, E, Visser, G R, Klotz, A, Benschop, C, Wulfert, F, Danner, S A, Wolf, F D, Jurriaans, S, Portegies, P, Colebunders, R, Pelgrom, J, Wijnants, H, DE Roo, A, Keersmaekers, K, Vandenbruane, M, Branden, D V D, James, T, Wanzeele, F V, Gucht, B V D, Van Der Ende, M E, Nouwen, J, Deenenkamp, R, Van Der Meyden, D, Koopmans, P P, Brinkman, K, Ver Hofstede, H, Zomer, B, Blok, W L, Ruissen, C, Sprenger, H, Law, G, Meulen, P V, Veen, C T, Juttmann, J R, Heul, C V, Santegoets, R, Ven, B V, Kate, R W T, Schoemaker, M, Kauffmann, R H, Henrichs, J M, Maat, A, Prins, E, Napel, C H H T, Pogany, K, Duyts, T, Simons, P, Lacor, P, Waele, A D, Wijngaarden, E V, Lejeune, M, Wijngaarden, E V, Lejeune, M, Nieuwkerk, P, Sprangers, M, Roos, M, Scholte, R, Dijkman, J, Japour, A J, Borst, M J & Leeuwen, E V 2000, ' Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine ', Clinical Infectious Diseases, vol. 31, no. 5, pp. 1234-1239 . https://doi.org/10.1086/317449
Clinical infectious diseases, 31, 1234-1239. Oxford University Press

Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f615f6536c6a96e7085c25f5eb7ec42c
https://pure.eur.nl/en/publications/beadb3d0-5a2a-44c7-85c9-eaddd275ab6c